GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (NAS:INO) » Definitions » Cyclically Adjusted PB Ratio

Inovio Pharmaceuticals (Inovio Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.48 (As of Apr. 27, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Inovio Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Inovio Pharmaceuticals's current share price is $10.57. Inovio Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $22.20. Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.48.

The historical rank and industry rank for Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

INO' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.19   Med: 3.05   Max: 18.5
Current: 0.46

During the past years, Inovio Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 18.50. The lowest was 0.19. And the median was 3.05.

INO's Cyclically Adjusted PB Ratio is ranked better than
75.2% of 641 companies
in the Biotechnology industry
Industry Median: 1.72 vs INO: 0.46

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Inovio Pharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2023 was $5.148. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $22.20 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Inovio Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Inovio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 5.52 2.85 0.84 0.28

Inovio Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.44 0.24 0.21 0.28

Competitive Comparison of Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Inovio Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=10.57/22.2
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inovio Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Inovio Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=5.148/129.4194*129.4194
=5.148

Current CPI (Dec. 2023) = 129.4194.

Inovio Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 25.733 99.695 33.406
201406 24.239 100.560 31.195
201409 23.170 100.428 29.859
201412 21.974 99.070 28.706
201503 20.372 99.621 26.466
201506 30.173 100.684 38.784
201509 32.109 100.392 41.393
201512 29.193 99.792 37.860
201603 28.390 100.470 36.570
201606 26.454 101.688 33.668
201609 23.829 101.861 30.276
201612 19.975 101.863 25.379
201703 17.020 102.862 21.414
201706 19.079 103.349 23.892
201709 21.532 104.136 26.760
201712 18.911 104.011 23.531
201803 14.949 105.290 18.375
201806 14.613 106.317 17.788
201809 13.161 106.507 15.992
201812 10.730 105.998 13.101
201903 9.546 107.251 11.519
201906 6.526 108.070 7.815
201909 4.082 108.329 4.877
201912 0.407 108.420 0.486
202003 15.159 108.902 18.015
202006 14.079 108.767 16.752
202009 23.201 109.815 27.343
202012 29.615 109.897 34.876
202103 33.340 111.754 38.610
202106 29.040 114.631 32.786
202109 25.874 115.734 28.933
202112 22.063 117.630 24.274
202203 18.812 121.301 20.071
202206 14.432 125.017 14.940
202209 12.828 125.227 13.258
202212 10.543 125.222 10.896
202303 9.099 127.348 9.247
202306 7.582 128.729 7.623
202309 6.147 129.860 6.126
202312 5.148 129.419 5.148

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Inovio Pharmaceuticals  (NAS:INO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Inovio Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Inovio Pharmaceuticals (Inovio Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Executives
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
David B. Weiner director 717 BEACOM LANE, MERION STATION PA 19066-1603
Simon X Benito director 967 LAWRENCE AVE, WESTFIELD NJ 07090
Michael John Sumner officer: Chief Medical Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Laurent Humeau officer: Chief Scientific Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jacqueline Elizabeth Shea officer: Chief Operating Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Peter Kies officer: CFO
Roger D Dansey director 21823 30TH DRIVE SE, BOTHELL WA 98021
Jong Joseph Kim director, officer: Chief Executive Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jay Shepard director 15977 GRANDVIEW AVENUE, MONTE SERENO CA 95030
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Wendy L Yarno director
Morton Collins director
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Niranjan Sardesai officer: Chief Operating Officer VGX PHARMACEUTICALS, INC., 450 SENTRY PARKWAY, BLUE BELL PA 19422